Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMD NASDAQ:CRNX NASDAQ:LNTH NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$11.12-1.1%$12.34$5.60▼$17.43$877.38M1.764.56 million shs1.83 million shsCRNXCrinetics Pharmaceuticals$35.89+2.0%$31.48$24.10▼$62.53$3.31B0.281.31 million shs1.70 million shsLNTHLantheus$51.47-3.3%$58.80$47.25▼$118.21$3.62B0.151.35 million shs1.20 million shsTLXTelix Pharmaceuticals$10.11-1.0%$11.45$8.93▼$30.36$3.46BN/A288,185 shs244,175 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix-1.75%+1.08%-18.14%-24.87%+49.67%CRNXCrinetics Pharmaceuticals-1.90%+2.87%+16.92%+17.31%-29.39%LNTHLantheus+2.25%+4.70%-5.22%-34.07%-52.37%TLXTelix Pharmaceuticals-6.59%+8.85%-16.31%-37.74%+1,020,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$11.12-1.1%$12.34$5.60▼$17.43$877.38M1.764.56 million shs1.83 million shsCRNXCrinetics Pharmaceuticals$35.89+2.0%$31.48$24.10▼$62.53$3.31B0.281.31 million shs1.70 million shsLNTHLantheus$51.47-3.3%$58.80$47.25▼$118.21$3.62B0.151.35 million shs1.20 million shsTLXTelix Pharmaceuticals$10.11-1.0%$11.45$8.93▼$30.36$3.46BN/A288,185 shs244,175 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix-1.75%+1.08%-18.14%-24.87%+49.67%CRNXCrinetics Pharmaceuticals-1.90%+2.87%+16.92%+17.31%-29.39%LNTHLantheus+2.25%+4.70%-5.22%-34.07%-52.37%TLXTelix Pharmaceuticals-6.59%+8.85%-16.31%-37.74%+1,020,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 2.88Moderate Buy$18.0061.87% UpsideCRNXCrinetics Pharmaceuticals 2.78Moderate Buy$63.4376.73% UpsideLNTHLantheus 2.71Moderate Buy$85.5066.12% UpsideTLXTelix Pharmaceuticals 2.83Moderate Buy$21.00107.72% UpsideCurrent Analyst Ratings BreakdownLatest CRMD, LNTH, TLX, and CRNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/24/2025CRNXCrinetics PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$53.00 ➝ $52.009/23/2025TLXTelix PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$23.00 ➝ $20.009/18/2025TLXTelix PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.009/16/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$109.00 ➝ $84.009/15/2025LNTHLantheusTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$95.00 ➝ $80.009/10/2025TLXTelix PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$23.00 ➝ $20.009/9/2025CRMDCorMedixJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$22.008/28/2025TLXTelix PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral8/28/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$22.008/11/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy ➝ Hold$111.00 ➝ $63.008/11/2025CRNXCrinetics PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$90.00 ➝ $86.00(Data available from 9/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$43.47M19.97N/AN/A$1.40 per share7.94CRNXCrinetics Pharmaceuticals$1.04M3,250.12N/AN/A$14.29 per share2.51LNTHLantheus$1.53B2.28$6.86 per share7.50$15.65 per share3.29TLXTelix Pharmaceuticals$516.72M6.62$0.11 per share89.41$1.12 per share9.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix-$17.93M$0.7514.8311.83N/A42.11%42.73%34.19%10/29/2025 (Estimated)CRNXCrinetics Pharmaceuticals-$298.41M-$4.11N/AN/AN/AN/A-32.28%-29.45%11/11/2025 (Estimated)LNTHLantheus$312.44M$3.7613.698.16N/A17.82%34.06%19.10%11/5/2025 (Estimated)TLXTelix Pharmaceuticals$32.93MN/A0.0021.06N/AN/AN/AN/AN/ALatest CRMD, LNTH, TLX, and CRNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CRMDCorMedix$0.20$0.28+$0.08$0.28$29.88 million$39.74 million8/7/2025Q2 2025CRNXCrinetics Pharmaceuticals-$1.13-$1.23-$0.10-$1.23$0.52 million$1.03 million8/6/2025Q2 2025LNTHLantheus$1.65$1.57-$0.08$1.12$389.69 million$378.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedixN/A7.827.52CRNXCrinetics PharmaceuticalsN/A17.8017.80LNTHLantheus0.494.294.07TLXTelix Pharmaceuticals0.992.782.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%CRNXCrinetics Pharmaceuticals98.51%LNTHLantheus99.06%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCRMDCorMedix5.30%CRNXCrinetics Pharmaceuticals4.60%LNTHLantheus1.50%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3078.06 million73.92 millionOptionableCRNXCrinetics Pharmaceuticals21094.18 million89.84 millionOptionableLNTHLantheus70067.99 million66.97 millionOptionableTLXTelix PharmaceuticalsN/A338.44 millionN/AN/ACRMD, LNTH, TLX, and CRNX HeadlinesRecent News About These CompaniesUBS Group Has Lowered Expectations for Telix Pharmaceuticals (NASDAQ:TLX) Stock PriceSeptember 24 at 2:06 AM | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Up 9.2% - Time to Buy?September 23 at 2:43 PM | marketbeat.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 23 at 11:15 AM | globenewswire.comCMS Grants Transitional Pass-Through Status for GozellixSeptember 23 at 10:15 AM | globenewswire.comUBS Group Issues Pessimistic Forecast for Telix Pharmaceuticals (NASDAQ:TLX) Stock PriceSeptember 23 at 10:09 AM | marketbeat.comTelix Pharmaceuticals Secures Key Reimbursement Status for GozellixSeptember 23 at 4:07 AM | msn.comAnalysts Set Telix Pharmaceuticals Limited (NASDAQ:TLX) Price Target at $21.50September 23 at 3:13 AM | americanbankingnews.comRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLXSeptember 22 at 6:50 PM | prnewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - Here's What HappenedSeptember 20, 2025 | marketbeat.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 20, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Coverage Initiated at CitigroupSeptember 20, 2025 | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Still a Buy?September 19, 2025 | marketbeat.comTelix Pharmaceuticals Limited (NASDAQ:TLX) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 19, 2025 | marketbeat.comCitigroup Begins Coverage on Telix Pharmaceuticals (NASDAQ:TLX)September 19, 2025 | marketbeat.comTelix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again -- Hagens BermanSeptember 19, 2025 | globenewswire.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You ...September 16, 2025 | bakersfield.comBTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 16, 2025 | globenewswire.comRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLXSeptember 15, 2025 | prnewswire.comTELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the FirmSeptember 15, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down After Analyst DowngradeSeptember 13, 2025 | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Given New $20.00 Price Target at HC WainwrightSeptember 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRMD, LNTH, TLX, and CRNX Company DescriptionsCorMedix NASDAQ:CRMD$11.12 -0.12 (-1.07%) Closing price 04:00 PM EasternExtended Trading$11.16 +0.04 (+0.40%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Crinetics Pharmaceuticals NASDAQ:CRNX$35.89 +0.71 (+2.02%) Closing price 04:00 PM EasternExtended Trading$36.18 +0.29 (+0.81%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Lantheus NASDAQ:LNTH$51.47 -1.76 (-3.31%) Closing price 04:00 PM EasternExtended Trading$52.17 +0.70 (+1.35%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Telix Pharmaceuticals NASDAQ:TLX$10.11 -0.10 (-0.98%) Closing price 04:00 PM EasternExtended Trading$10.12 +0.02 (+0.15%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas It's a Good Time to Build a Position in KB Home Alphabet: Time to Take Profits, Buy, or Wait for a Pullback? Cintas Stock Sends a Clear Buy Signal as Momentum Builds Thor Industries Tracking for New Highs in 2026 Micron’s Stock Price Rally Is Not Over: MU $190 Is Coming Soon NuScale Power: The SMR Stock at the Heart of the AI Energy Boom Intel + NVIDIA: The Unexpected AI Alliance Shaking Wall Street Why Traders Are Doubling Down on SoundHound Stock After Big Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
